|
News For VVUS;TSN;DELL;ALKS;MCK;GDOT;MRK;LTM;NFLX;CTRP;ADNC;ELN;MAT From The Last 14 Days Check below for free stories on VVUS;TSN;DELL;ALKS;MCK;GDOT;MRK;LTM;NFLX;CTRP;ADNC;ELN;MAT the last two weeks. |
|
|
| June 18, 2013 |
| 17:16 EDT |  | DELL | Dell special committee responds to Carl Icahn's latest proposal
 Subscribe for More Information |
|
| 16:20 EDT | | DELL | Southeastern says Icahn in best position to lead alternative Dell transaction
In a regulatory filing Southeastern Asset Management stated: "Southeastern Asset Management continues to believe that the Michael Dell / Silver Lake management buyout proposal undervalues the company and its prospects going forward. Southeastern and Icahn Associates have been working diligently to provide a better alternative for shareholders.Southeastern has determined that Icahn is in the best position to lead the development of an alternative transaction and to generate a better outcome for shareholders. Southeastern has therefore agreed to sell approximately 72,010,328 shares to Icahn, making Icahn the largest outside shareholder of Dell. Southeastern intends to vote its approximately 72,010,328 remaining shares of Dell stock against the $13.65 Michael Dell / Silver Lake management buyout proposal. Furthermore, Southeastern intends to vote its shares at Dell’s Annual Meeting in favor of the slate of highly qualified director candidates it and Icahn submitted to the Company. Icahn has Southeastern’s full support as it leads the proxy fight in the interest of all shareholders against the undervalued management buyout proposal. Southeastern will continue to participate in the proxy contest with Icahn to defeat the Michael Dell / Silver Lake management buyout proposal." |
|
| 16:06 EDT | | DELL | Icahn reports 8.68% stake in Dell
|
|
| 16:00 EDT |  | MRK | Options Update; June 18, 2013
Subscribe for More Information |
|
| 12:49 EDT | | DELL | Icahn proposes Dell engage in $14 per share tender offer
Subscribe for More Information |
|
| 12:32 EDT | | DELL | Icahn says bought 72M Dell shares from Southeastern
Subscribe for More Information |
|
| 12:28 EDT | | DELL | Icahn proposes Dell commence tender offer for 1.1B shares at $14
Subscribe for More Information |
|
| 12:27 EDT | | DELL | Icahn issues letter to Dell holders, proposes $14/share tender offer
Subscribe for More Information |
|
| 11:48 EDT | | NFLX | Stocks with call strike movement; NFLX BTU
Subscribe for More Information |
|
| 11:47 EDT | | TSN | Hormel Foods falls after lowering profit outlook
Subscribe for More Information |
| |
| 09:38 EDT | | NFLX | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM |
|
| 09:30 EDT | | DELL | Dell tells holders $13.65/share offer 'superior to any alternative'
Subscribe for More Information |
|
| 08:52 EDT | | ELN | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:37 EDT |  | MRK | Drug companies turn to microchips to test medicines, WSJ reports
Subscribe for More Information |
|
| 08:36 EDT |  | ELN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. |
|
| 07:42 EDT |  | DELL | O'Reilly Media to hold a conference
Subscribe for More Information |
|
| 06:46 EDT | | ELN | Royalty Pharma announces withdrawal of judicial review, lapse of offer
Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel's decision requiring it to lapse its offer for Elan if, among other things, Elan shareholders approved the Share Repurchase Program. As a result, Royalty Pharma's offer has now lapsed. Accordingly, no Further Revised Acceptance Documents should be executed and delivered and any Acceptance Documents in respect of the Offer, the Increased Offer and Further Increased Offer are now of no legal effect. |
|
| 06:10 EDT | | MAT | Mattel subsidiary to grow broadcast and online presence
Subscribe for More Information |
|
| 06:08 EDT | | ELN | Court designates lead plaintiff in shareholder suit against SAC, Reuters reports
Subscribe for More Information |
|
| 05:39 EDT | | ELN | Elan advises holders to withdraw acceptances of Royalty Pharma Offer
Subscribe for More Information |
| |
|
|
|
|
